Lipid-lowering drugs Flashcards
Atherosclerosis can cause
CVD as blocks coronary arteries
Intermittent claudication in calf
Hyperlipidaemia Type I
High postprandial chylomicrons
From LPL (or related cofactor) deficiency
Raised TAGs, normal cholesterol
Hyperlipidaemia Type IIa
High LDLs
From lack of LDL receptor or mutations
Raised cholesterol, normal TAGs
Hyperlipidaemia Type IIb
High VLDL and LDL
From familial combined hyperlipidaemia (genetic)
Raised cholesterol and TAGs
Hyperlipidaemia Type III
High IDL
From dysbetalipoproteinaemia, issues with Apo E so IDLs accumulate and some converted to LDL
High cholesterol and TAG
Hyperlipidaemia Type IV
High VLDL
From familial hypertriglyceridaemia (also increased risk of metabolic disease so higher risk of CV event)
Raised TAGs, normal cholesterol
Primary Prevention group (highest risk group factors)
Familial hyperlipidaemias
Diabetes
Chronic Kidney Disease
10 yr CV risk >10%
Secondary Prevention (2nd high risk group)
All with established CV risk and previous events
Treatments for lipid lowering
Lifestyle changes Statins (HMG CoA reductase inhibitor) Ezetimibe Fibrates Lomitapide
Not recommended for CV risk reduction:
Bile acid sequestrants, nicotinic acid, Omega-3
Statins MOA
Atorvastatin, simvastatin, pravastatin etc
HMG CoA reductase inhibitor, the rate limiting step in cholesterol synthesis so less synthesis, more LDL receptors expressed on hepatocytes
Ezetimibe MOA
Inhibits intestinal cholesterol absorption
Fibrates MOA
bezafibrate, fenofibrate, gemfibrozil etc
Acts as ligand for PPAR-alpha and increases FA oxidation in liver + muscle cells, and activates LPL
BA sequestrants MOA
aka anion exchange resins: colestyramine, colestipol
Bind to + inhibit intestinal BA reabsorption so fats excreted, BA conversion increased so more LDL pulled in from plasma for conversion
Nicotinic acid MOA
Reduces VLDL release, plasma triglyceride and cholesterol, and increases HDL
Omega-3
Have effect on TAGs and some on cholesterol but no clinical trials showing CVD prevention effectiveness
May be used to treat hypertriglyceridaemia as an adjunct